ARTICLE | Clinical News
RSD1235 CR oral: Phase Ic data
September 5, 2005 7:00 AM UTC
Data from a dose-escalation, European Phase Ic trial in 55 healthy volunteers showed that oral RSD1235 was well tolerated at all tested doses. The maximum dose of 900 mg twice-daily showed similar pla...